Azitra, Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $3.3 million compared to $2.9 million in the prior year period. Research and development expenses remained flat at $1.4 million, while general and administrative expenses increased to $2.1 million from $1.5 million. The company held $6.7 million in cash and cash equivalents as of June 30, 2026. Operationally, Azitra announced positive preclinical data for ATR-COSF supporting advancement toward a proof-of-concept clinical study, continued enrollment in the Phase 1/2 trial for ATR-04 with topline data expected in Q4 2026, and plans to pause further enrollment in the ATR-12 Netherton syndrome study. Azitra is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and novel products across therapeutics, cosmeceuticals, and biotechnology applications.

Azitra, Inc. announced ex vivo human skin study results for its ATR-COSF program, which utilizes a recombinant human filaggrin protein supernatant. The first study demonstrated that multiple applications of a 2% lyophilized supernatant in a hydrogel formulation increased protein penetration and distribution into the stratum granulosum compared to single-dose applications. A second study showed that the supernatant increased skin elasticity in a dose-dependent manner, with a 7.5% w/w concentration providing a 4.4-fold increase and a 0.28% w/w concentration restoring elasticity to levels seen in healthy skin. The company plans to optimize formulations and initiate human studies following these results. Azitra is a clinical-stage biopharmaceutical company developing precision dermatology therapies and cosmetic proteins.

On June 15, 2026, Azitra, Inc. filed a certificate of amendment to increase its authorized common stock from 200,000,000 to 750,000,000 shares. Stockholders also approved the Board's authority to effect one or more reverse stock splits and authorized the issuance of more than 19.99% of outstanding shares related to securities purchase agreements with Alumni Capital LP and other investors. Stockholders rejected a proposal to amend and restate the 2023 Stock Incentive Plan to increase the authorized share reserve. The company operates in the biotechnology industry, focusing on the development of novel therapeutics and vaccines.